- What is targeted therapy?
- How does targeted therapy work?
- Types of targeted therapy used today
- What’s the goal of targeted therapy treatment?
- Getting targeted therapy treatment
- Side effects of targeted therapy drugs
- When to call your doctor
- Other questions you may have about targeted therapy
- Emotions and targeted therapy treatment
- Paying for targeted therapy
- To learn more
To learn more
More information from your American Cancer Society
Here is more information you might find helpful. You also can order free copies of our documents from our toll-free number, 1-800-227-2345, or read them on our website, www.cancer.org.
Communication is key
Talking With Your Doctor (also in Spanish)
Helping Children When a Family Member Has Cancer: Dealing With Treatment (also in Spanish)
Living with cancer
After Diagnosis: A Guide for Patients and Families (also in Spanish)
Guide to Controlling Cancer Pain (also in Spanish)
Nutrition for Children With Cancer (also available in Spanish)
Sexuality for the Man With Cancer (also in Spanish)
Sexuality for the Woman With Cancer (also in Spanish)
Cancer treatment information
Understanding Chemotherapy: A Guide for Patients and Families (also in Spanish)
Understanding Radiation Therapy: A Guide for Patients and Families (also in Spanish)
Understanding Cancer Surgery: A Guide for Patients and Families (also in Spanish)
Clinical Trials: What You Need to Know (also in Spanish)
Cancer treatment side effects
Along with the above, the American Cancer Society has information about many different cancer treatment drugs and their side effects.
Insurance and money matters
Health Insurance and Financial Assistance for the Cancer Patient (also in Spanish)
In Treatment: Financial Guidance for Cancer Survivors and Their Families (also in Spanish)
Prescription Drug Assistance Programs (also in Spanish)
Along with the above, the American Cancer Society has information about many different types of cancer and how they are treated.
National organizations and Web sites*
Along with the American Cancer Society, other sources of information and support include:
National Cancer Institute
Toll-free number: 1-800-4-CANCER 1-800-422-6237
For up-to-date cancer information, including information for caregivers and family members, and to find a clinical trial that may be right for you
Job Accommodation Network
Toll-free number: 1-800-526-7234
A free consulting service of the US Department of Labor that gives information to help you keep your job (and insurance) during cancer treatment. Offers information on your rights under the Americans with Disabilities Act, and how to talk with your employer
No matter who you are, we can help. Contact us anytime, day or night, for cancer-related information and support. Call us at 1-800-227-2345 or visit www.cancer.org.
Agha R, Kinahan K, Bennett CL, Lacouture ME. Dermatologic challenges in cancer patients and survivors. Oncology. 2007;21:1462-1472.
Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008;26:3460-3462.
Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. J Natl Compr Canc Netw. 2009;7 Suppl 1:S5-S21.
Community Oncology Conference Highlights. Managing toxicities of EGFR inhibitors. 2008;5:202-203.
Esper P, Gale D, Muehlbauer P. What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs. 2007;11:659-666.
Kyriakou F, Kountourakis P, Papamichael D. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Targ Oncol. 2011;6: 245-251.
Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351-7.
Lacouture ME, West DP, Tigue CC, Knox K, Bennett CL. Cutaneous toxicities of targeted cancer therapies. Community Oncology. 2008;5(7):413-414.
Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol. 2009;4(2):107-19.
Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610-621.
Moore SH, O'Connell MJ, Wilkes GM. Optimizing Outcomes for Metastatic Colorectal Cancer Patients: An APN Roundtable Discussion. Institute for Medical Education & Research. March 2008.
National Cancer Institute. Targeted Cancer Therapies. Accessed at www.cancer.gov/cancertopics/factsheet/Therapy/targeted on June 28, 2013.
Ocvirk J, Heeger S, McCloud P, Hofheinz RD. A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol. 2013 May 21;47(2):166-75. doi: 10.2478/raon-2013-0014. Print 2013 Jun.
Voskens CJ, Goldinger SM, Loquai C, Robert C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.
Last Medical Review: 07/12/2013
Last Revised: 07/12/2013